{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:15:29Z","timestamp":1789964129383,"version":"4.0.1"},"reference-count":162,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Anthemis Consulting Ltd."},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006413","name":"Ariad","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006413","name":"Ariad","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ChemGenex"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clml.2013.03.018","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T22:43:11Z","timestamp":1374792191000},"page":"515-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options"],"prefix":"10.1016","volume":"13","author":[{"given":"Elias J.","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.03.018_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.clml.2013.03.018_bib2","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clml.2013.03.018_bib4","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib5","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.4.2013. \u00a9 National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed March 15, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u00ae, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf."},{"key":"10.1016\/j.clml.2013.03.018_bib6","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2013.03.018_bib7","first-page":"S1","article-title":"NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O'Brien","year":"2011","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2013.03.018_bib8","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib9","article-title":"The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy","volume":"118","author":"Marin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib11","article-title":"Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data","volume":"120","author":"Saglio","year":"2012","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib12","volume":"120","author":"Hochhaus","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib14","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.03.018_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.03.018_bib16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.03.018_bib17","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib19","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib20","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib22","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V99.2.713","article-title":"Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in\u00a0vitro resistance to STI571","volume":"99","author":"Jorgensen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib25","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3495.3495","article-title":"Functional characterization of ABCG2 polymorphisms and their influence on tyrosine kinase inhibitor effects in chronic myeloid leukemia cells","volume":"118","author":"Skoglund","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib27","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate gene polymorphisms to predict response and resistance to imatinib mesylate therapy in chronic myeloid leukemia","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","article-title":"Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment","volume":"162","author":"Galimberti","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2013.03.018_bib30","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2003-01-0083","article-title":"Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in\u00a0vitro","volume":"102","author":"Ferrao","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib31","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2013.03.018_bib32","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1582-4934.2007.00108.x","article-title":"Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors","volume":"11","author":"Li","year":"2007","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.clml.2013.03.018_bib33","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Danhauser-Riedl","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib34","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib35","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1309\/AJCPQFSC9ZJNMAZ6","article-title":"Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission","volume":"135","author":"Sun","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2013.03.018_bib37","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12032-010-9781-z","article-title":"BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?","volume":"29","author":"Gruber","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib39","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib40","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"O'Dwyer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib42","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2013.03.018_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2013.03.018_bib45","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"San Jos\u00e9-Eneriz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib47","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2013.03.018_bib50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","article-title":"Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review","volume":"87","author":"Vaidya","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.03.018_bib51","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib52","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","article-title":"Characterization of cancer stem cells in chronic myeloid leukaemia","volume":"35","author":"Jorgensen","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.clml.2013.03.018_bib53","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Rosee","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2013.03.018_bib55","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib56","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib57","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib58","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2011.11.002","article-title":"Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression","volume":"39","author":"Ernst","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib60","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients. The GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib61","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.03.018_bib63","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib64","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib65","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib66","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3324\/haematol.2009.014712","article-title":"Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"95","author":"Kim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.03.018_bib67","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib68","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib69","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib70","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.clml.2013.03.018_bib71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2013.03.018_bib73","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.03.018_bib74","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2013.03.018_bib75","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib76","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1934.1934","article-title":"In early-chronic phase chronic myeloid leukemia patients treated with imatinib, resistance is rarely mediated by Abl kinase domain mutations","volume":"110","author":"Soverini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib77","article-title":"Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment","volume":"116","author":"Kim","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: molecular monitoring in clinical practice","author":"Branford","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2013.03.018_bib80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2013.03.018_bib81","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571","volume":"277","author":"Corbin","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.03.018_bib82","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib83","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib84","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib85","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib86","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.clml.2013.03.018_bib87","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.03.018_bib88","article-title":"BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"2","author":"Terasawa","year":"2010","journal-title":"PLoS Curr"},{"key":"10.1016\/j.clml.2013.03.018_bib89","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"BCR-ABL1 kinase domain mutations: methodology and clinical evaluation","volume":"87","author":"Alikian","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.03.018_bib90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology","volume":"11","author":"Jones","year":"2009","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2013.03.018_bib91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MOH.0b013e32834399ef","article-title":"Mutational analysis in chronic myeloid leukemia: when and what to do?","volume":"18","author":"Branford","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2013.03.018_bib92","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A\u00a0co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib","volume":"94","author":"Ernst","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.03.018_bib93","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib94","article-title":"Real-life rates of disease monitoring in clinical practice in Europe: the \u201cunmet needs in CML and Ph+ALL\u201d (UNIC) study","volume":"118","author":"Morra","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib95","first-page":"138","article-title":"Molecular monitoring of BCR-ABL transcripts\u2014standardization needed to properly use, and further investigate the value of, a critical surrogate marker for success in therapy of chronic myeloid leukemia","volume":"7","author":"Giles","year":"2011","journal-title":"US Oncol Hematol"},{"key":"10.1016\/j.clml.2013.03.018_bib96","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.03.018_bib97","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib98","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3747\/co.v18i2.391","article-title":"Monitoring response and resistance to treatment in chronic myeloid leukemia","volume":"18","author":"Assouline","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib99","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clml.2011.06.009","article-title":"The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?","volume":"11","author":"Cortes","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2013.03.018_bib100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib101","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib102","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib103","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib104","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2004-12-4764","article-title":"Can we afford to let sleeping dogs lie?","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib105","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.03.018_bib106","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2013.03.018_bib107","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.clml.2011.03.032","article-title":"Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation","volume":"11","author":"Cornelison","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2013.03.018_bib108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.leukres.2010.04.010","article-title":"Pegylated IFN-alpha2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone","volume":"35","author":"Nicolini","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.03.018_bib109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95","author":"Itonaga","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2013.03.018_bib110","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In\u00a0vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib111","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib112","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib113","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib114","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib115","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.03.018_bib117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(07)70078-5","article-title":"Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL","volume":"8","author":"Soverini","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib118","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In\u00a0vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib119","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2013.03.018_bib120","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib121","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib122","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes","volume":"114","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib123","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib124","article-title":"A\u00a0phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib","volume":"25","author":"Giles","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib125","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib126","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In\u00a0vitro and in\u00a0vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib127","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib128","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib129","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3785.3785","article-title":"Bosutinib as therapy for chronic phase chronic myeloid leukemia following failure with imatinib plus dasatinib and\/or nilotinib: 24-month minimum follow-up update","volume":"120","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib130","article-title":"Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 36-month minimum follow-up update","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib131","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.03.018_bib132","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib133","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.915.915","article-title":"Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myeloid leukemia (AP-CML or BP-CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL): 12-month follow-up of the PACE trial","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib134","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a Phase I trial of the BCR-ABL\/IGF- 1R\/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib135","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","article-title":"Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib136","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.864.864","article-title":"Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib137","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib138","article-title":"Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia","volume":"26","author":"Foran","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib139","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2967.2967","article-title":"A\u00a0Phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed\/refractory AML, ALL and MDS or resistant\/intolerant CML","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib140","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib141","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter Phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib142","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter Phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib143","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2193.2193","article-title":"A\u00a0Phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib","volume":"114","author":"Ayoubi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib144","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2760.2760","article-title":"Bosutinib safety profile and management of toxicities in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"118","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib146","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2013.03.018_bib147","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2481.2481","article-title":"Partially or fully BCR-ABL independent mechanisms of in\u00a0vitro resistance to ponatinib","volume":"118","author":"Yu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib148","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.474.474","article-title":"Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228","volume":"110","author":"Shah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib149","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.018_bib150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358)\u2013a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor","volume":"184","author":"Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.clml.2013.03.018_bib151","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/138161211795049778","article-title":"Omacetaxine as an anticancer therapeutic: what is old is new again","volume":"17","author":"Wetzler","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clml.2013.03.018_bib152","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.018_bib153","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":"Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells","volume":"25","author":"Allan","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib154","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/14656566.9.6.1029","article-title":"Homoharringtonine for the treatment of chronic myelogenous leukemia","volume":"9","author":"Quintas-Cardama","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib155","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant\/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Nicolini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib156","article-title":"Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Akard","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib157","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3753.3753","article-title":"Blast phase chronic myeloid leukemia: a pooled analysis of subcutaneous omacetaxine mepesuccinate in treatment-resistant patients","volume":"120","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2013.03.018_bib158","article-title":"Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Wetzler","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib159","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/sj.leu.2402775","article-title":"Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs","volume":"16","author":"Tipping","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.03.018_bib160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2011.09016.x","article-title":"Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation","volume":"157","author":"Coude","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.03.018_bib161","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative in\u00a0vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.018_bib162","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000323662","article-title":"Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"126","author":"Oyekunle","year":"2011","journal-title":"Acta Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:36Z","timestamp":1761870276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":162,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S2152265013001201"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}